NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
Clinical Trials
25 trialsNCT00535314 2025-05-31
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
Biogen
Phase 2 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT02535078 2024-07-24
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
Phase 1/2 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT05496192 2023-04-14
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT04759846 2023-02-21
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
Phase 1 Withdrawn
NCT05572463 2022-11-18
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Withdrawn
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT02854488 2022-03-31
Yervoy Pregnancy Surveillance Study
Bristol-Myers Squibb
Withdrawn
NCT04995094 2021-11-05
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
HiberCell, Inc.
Phase 2 Withdrawn
NCT04955262 2021-07-08
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Nektar Therapeutics
Phase 1 Withdrawn
NCT04060407 2021-06-01
CINDI
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Withdrawn
NCT03773744 2021-04-06
Pelican
Turnstone Biologics, Corp.
Phase 1 Withdrawn
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02447939 2018-09-14
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
Phase 1 Withdrawn
NCT03205722 2018-04-09
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
Bristol-Myers Squibb
Withdrawn
NCT01765556 2016-11-02
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Withdrawn
NCT02862145 2016-09-27
MRX34-102
Mirna Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT01764009 2015-09-11
AIMM
Valerio Therapeutics
Phase 1/2 Withdrawn
NCT01933061 2014-02-04
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene
Phase 2 Withdrawn
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT00803374 2011-11-21
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Bristol-Myers Squibb
Phase 1 Withdrawn